Clinical treatment progress of pseudomyxoma peritonei syndrome / 肿瘤研究与临床

ABSTRACT

Pseudomyxoma peritonei syndrome (PMP) is characterized by a gradual expansion of mucoid tumour and fluid at specific sites within abdominopelvic regions as a result of a perforated appendiceal adenoma. The standard therapy for PMP is combining cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy. Maximal tumor debulking surgery (MTD) may be beneficial in patients in whom complete cytoreductive surgery (CCRS) cannot be achieved. It is now recognized that CCRS is one of the strongest predictors of long term survival in patients with PMP. The 5-year survival rate in patients who underwent CCRS was 80.0 %-87.4 %, however the rate in patients who underwent MTD was only 24.0 %-39.2 %.This article reviews the pathological classification,diagnosis and treatment of PMP.